Terns Pharmaceuticals Inc
F:430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Terns Pharmaceuticals Inc
F:430
|
US |
|
US Physical Therapy Inc
NYSE:USPH
|
US |
|
B
|
Build-A-Bear Workshop Inc
F:FPW
|
US |
|
S
|
Sprouts Farmers Market Inc
XBER:1FA
|
US |
|
1
|
1-800-Flowers.Com Inc
F:FWC
|
US |
|
N
|
New Oriental Education & Technology Group Inc
F:N1U
|
CN |
|
S
|
Stantec Inc
F:S3A
|
CA |
|
I
|
iRobot Corp
F:I8R
|
US |
Terns Pharmaceuticals Inc
Terns Pharmaceuticals is a biopharmaceutical company that develops oral small-molecule drugs for serious diseases such as cancer and metabolic liver disease. Its work is mostly about finding drug candidates, testing them in clinical trials, and deciding which programs are worth advancing or partnering with larger drugmakers. The company does not sell a broad range of consumer products; it is trying to turn its research into approved medicines. Its main customers are not patients today but future ones, along with pharmaceutical partners that may license or co-develop its drug programs. Terns can make money by licensing drug rights, receiving milestone and collaboration payments, and, if a drug reaches the market, through product sales or royalty streams. That makes it different from a traditional drug seller: most of its value comes from building a pipeline of experimental medicines and proving they can become useful treatments.
Terns Pharmaceuticals is a biopharmaceutical company that develops oral small-molecule drugs for serious diseases such as cancer and metabolic liver disease. Its work is mostly about finding drug candidates, testing them in clinical trials, and deciding which programs are worth advancing or partnering with larger drugmakers. The company does not sell a broad range of consumer products; it is trying to turn its research into approved medicines.
Its main customers are not patients today but future ones, along with pharmaceutical partners that may license or co-develop its drug programs. Terns can make money by licensing drug rights, receiving milestone and collaboration payments, and, if a drug reaches the market, through product sales or royalty streams. That makes it different from a traditional drug seller: most of its value comes from building a pipeline of experimental medicines and proving they can become useful treatments.
